Researchers have been advancing towards an innovative breakthrough in the HIV treatment. This breakthrough comes with a synthetic human growth hormone factor. A synthetic human growth hormone-releasing factor has significant beneficial effects on ‘lipid profiles and visceral obesity in patients with HIV-associated lipodystrophy’.
Ongoing clinical trials divided in to phased testing’s have revealed various other findings in addition to this breakthrough. Results from a phase III trial show that there is an analogy between the new factor and typical characteristics observed in the HIV patients.
The researchers explained about this new finding that, “Tesamorelin“is a synthetic human growth hormone releasing factor GHRH (1-44) analogue with a trans-3-hexenoyl group added to the N-terminal to increase the half-life over that of native GHRH (1-44)”.
continue reading Synthetic Human Growth Hormone Releasing Factor: A Breakthrough in HIV Treatment











